- Home
- NUVL vs JOBY Comparison
NUVL vs JOBY Comparison
Compare NUVL & JOBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- JOBY
- Stock Information
- Founded
- NUVL 2017
- JOBY 2009
- Country
- NUVL United States
- JOBY United States
- Employees
- NUVL N/A
- JOBY N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- JOBY Aerospace
- Sector
- NUVL Health Care
- JOBY Consumer Discretionary
- Exchange
- NUVL Nasdaq
- JOBY Nasdaq
- Market Cap
- NUVL 6.7B
- JOBY 6.1B
- IPO Year
- NUVL 2021
- JOBY N/A
- Fundamental
- Price
- NUVL $75.84
- JOBY $8.19
- Analyst Decision
- NUVL Strong Buy
- JOBY Strong Buy
- Analyst Count
- NUVL 11
- JOBY 5
- Target Price
- NUVL $112.36
- JOBY $9.30
- AVG Volume (30 Days)
- NUVL 558.9K
- JOBY 18.7M
- Earning Date
- NUVL 02-25-2025
- JOBY 02-19-2025
- Dividend Yield
- NUVL N/A
- JOBY N/A
- EPS Growth
- NUVL N/A
- JOBY N/A
- EPS
- NUVL N/A
- JOBY N/A
- Revenue
- NUVL N/A
- JOBY $1,113,000.00
- Revenue This Year
- NUVL N/A
- JOBY N/A
- Revenue Next Year
- NUVL N/A
- JOBY $8,570.53
- P/E Ratio
- NUVL N/A
- JOBY N/A
- Revenue Growth
- NUVL N/A
- JOBY N/A
- 52 Week Low
- NUVL $61.80
- JOBY $4.50
- 52 Week High
- NUVL $113.51
- JOBY $10.72
- Technical
- Relative Strength Index (RSI)
- NUVL 38.09
- JOBY 49.06
- Support Level
- NUVL $69.58
- JOBY $7.73
- Resistance Level
- NUVL $78.18
- JOBY $10.72
- Average True Range (ATR)
- NUVL 3.03
- JOBY 0.68
- MACD
- NUVL 0.04
- JOBY -0.16
- Stochastic Oscillator
- NUVL 50.40
- JOBY 15.38
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About JOBY Joby Aviation Inc.
Joby Aviation Inc is a transportation company developing electric air taxis for commercial passenger service.